Recent advances in immunotherapy for hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• Immunotherapy and Cancer Treatment

Background:

• Advanced hepatocellular carcinoma (HCC) presents treatment challenges due to late diagnosis and underlying liver conditions.
• Conventional chemotherapy and current targeted agents like sorafenib offer limited efficacy in HCC management.

Purpose of the Study:

• To review recent advancements in immune-based treatment strategies for advanced HCC.
• To evaluate the clinical impact and future directions of immunotherapy in HCC.

Main Methods:

• Comprehensive literature search of PubMed up to January 2021 for immune-based HCC treatments.
• Inclusion of clinical trial data from clinicaltrials.gov.

Main Results:

• Immune checkpoint inhibitors (ICIs) like nivolumab and pembrolizumab have transformed HCC therapy, with combination ICIs also gaining approval.
• Immunotherapies demonstrate superior safety, tolerability, and survival benefits compared to targeted drugs.
• Other immunotherapeutic approaches, including cancer vaccines and cell-based therapies, show promise in clinical trials, alongside identified biomarkers for guiding ICI treatment decisions.

Conclusions:

• Immunotherapy is now a primary treatment for advanced HCC, surpassing traditional methods.
• Challenges remain, including low response rates and acquired resistance to immunotherapy in HCC patients.
• Further investigation into resistance mechanisms and discovery of predictive biomarkers are crucial for optimizing HCC immunotherapy.